MedTrace Logo

Efficacy and Safety of LC-Z300-01 in Chinese With Type 2 Diabetes

NCT06847178 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-02-26

No results posted yet for this study

Summary

This trial is conducted in China. The aim of the trial is to investigate the efficacy and safety of an Bamboo cane polysaccharide (oral LC-Z300-01) in subjects with type 2 diabetes.

Conditions

Interventions

DIETARY_SUPPLEMENT

Placebo twice daily in blinding

Administered placebo twice-daily for 12 weeks in blinding

DRUG

Low-dose LC-Z300-01 twice daily in blinding

Administered twice-daily for 12 weeks in blinding

DRUG

High-dose LC-Z300-01 twice daily in blinding

Administered twice-daily for 12 weeks in blinding

DRUG

High-dose LCZ300-1 twice daily in open-label

Administered high-dose LCZ300-1 twice-daily for 12 weeks in open-label

Sponsors & Collaborators

  • Shanghai Changzheng Hospital

    lead OTHER

Principal Investigators

  • Wei-fen Xie, Prof. · Shanghai Changzheng Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2025-10-31
Completion
2025-11-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06847178 on ClinicalTrials.gov